In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of $185.00. The company’s shares closed last Friday at $166.41.
Raymond covers the Healthcare sector, focusing on stocks such as Biogen, BioMarin Pharmaceutical, and Vertex Pharmaceuticals. According to TipRanks, Raymond has an average return of 3.6% and a 48.80% success rate on recommended stocks.
AbbVie has an analyst consensus of Strong Buy, with a price target consensus of $186.31, an 11.96% upside from current levels. In a report released on April 18, Wells Fargo also maintained a Buy rating on the stock with a $200.00 price target.
The company has a one-year high of $181.20 and a one-year low of $125.85. Currently, AbbVie has an average volume of 5.65M.
Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AbbVie (ABBV) Company Description:
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Read More on ABBV:
- Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
- AbbVie reports ‘positive’ results from Phase 3 SELECT-GCA study of upadacitinib
- Fake Botox Fight Sends AbbVie (NASDAQ:ABBV) Up Fractionally
- AbbVie Stock (NYSE:ABBV): Humira Leads Market with 96% Share
- AbbVie presents results from ongoing Phase 3 study of oral atogepant
